Enveric Biosciences, Inc.
ENVB
$1.21
-$0.08-6.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 225.50% | -40.61% | -60.35% | -34.41% | -76.69% |
| Depreciation & Amortization | -2.60% | -1.74% | -1.97% | -1.27% | -2.08% |
| Other Operating Expenses | -129.57% | -- | -- | -- | -- |
| Total Operating Expenses | 33.11% | -39.59% | -67.02% | -49.03% | -50.35% |
| Operating Income | -33.11% | 39.59% | 67.02% | 49.03% | 50.35% |
| Income Before Tax | 7.80% | 25.98% | 70.43% | 47.51% | 66.41% |
| Income Tax Expenses | -67.71% | -- | -- | -- | 101.50% |
| Earnings from Continuing Operations | 8.19% | 26.16% | 70.43% | 47.47% | 60.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.19% | 26.16% | 70.43% | 47.47% | 60.41% |
| EBIT | -33.11% | 39.59% | 67.02% | 49.03% | 50.35% |
| EBITDA | -34.42% | 40.56% | 68.01% | 49.90% | 51.23% |
| EPS Basic | 78.73% | 81.63% | 91.84% | 73.42% | 64.37% |
| Normalized Basic EPS | 78.64% | 81.59% | 91.79% | 72.74% | -14.95% |
| EPS Diluted | 78.73% | 81.63% | 91.84% | 73.42% | 64.37% |
| Normalized Diluted EPS | 78.64% | 81.59% | 91.79% | 72.74% | -14.95% |
| Average Basic Shares Outstanding | 331.65% | 302.08% | 260.07% | 92.50% | 9.57% |
| Average Diluted Shares Outstanding | 331.65% | 302.08% | 260.07% | 92.50% | 9.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |